Gene Therapy Treatments for Congenital Deafness

🚨 Major News in Gene Therapy: The U.S. FDA has approved Otarmeni, a gene therapy from Regeneron Pharmaceuticals Inc, for the treatment of a rare genetic form of hearing loss caused by mutations in the OTOF gene. Key Highlights: - First-ever gene therapy approved for genetic hearing loss - Targets otoferlin-related deafness (OTOF gene mutation) - Works by delivering a functional copy of the OTOF gene to inner ear cells - Uses a modified viral vector delivered directly into the cochlea - Addresses a rare condition affecting ~20–50 newborns per year in the U.S. Why it matters: ✔ Marks a historic first for gene therapy in sensory disorders ✔ Shifts the treatment paradigm from managing hearing loss → correcting its genetic cause ✔ Opens the door for broader applications of inner-ear and CNS gene delivery technologies ✔ Signals accelerating momentum in precision medicine for ultra-rare diseases ✔ Therapy is expected to be made available free to U.S. patients What a day for gene therapy. Certainly a significant milestone for patients, Regeneron - bringing functional hearing restoration closer to reality for children born with inherited deafness. #genetherapy #pharma #biotech #CGTweekly

Gene therapy restores hearing, even in a 24-year-old who was born deaf (which is a big deal, not just for them but also the science): 🧬A single shot of gene therapy restored hearing in 10 patients aged 1 to 24 with congenital deafness caused by OTOF gene mutations 🧬 While this is not the first Gene therapy for deafness, the surprise was the 14- and 24-year-old participants saw dramatic improvements, something researchers didn’t expect based on previous studies 🧬 Average hearing improved from 106 decibels (profound deafness) to 52 (functional range) within six months 🧬 Hearing gains were often rapid, with most patients showing improvement within the first month 🧬 One 7-year-old recovered enough to hold daily conversations and hear rain for the first time, despite having a cochlear implant in the other ear 🧬 The therapy uses an adeno-associated virus to deliver a working copy of the OTOF gene through a single injection to the inner ear #digitalhealth

Being born with severe genetic deafness was once considered a completely permanent biological condition. Scientists recently achieved a massive medical breakthrough by successfully restoring hearing in ten completely deaf patients using a single revolutionary gene therapy injection. These individuals originally suffered from a specific genetic mutation that physically prevented their inner ears from producing a vital protein required to send sound signals directly to the brain. Researchers ingeniously solved this problem by using a harmless synthetic virus to deliver a fully functional copy of the missing gene straight into the cochlea. Within just six months all the clinical participants saw their sound detection dramatically improve from an average of 106 decibels down to a remarkable 52 decibels. This incredible technological advancement proves that actively repairing broken DNA can successfully cure congenital hearing loss and permanently transform vulnerable human lives. Source: Nature Medicine

Gene therapy just gave a 7-year-old her hearing back. Not partial. Not assistive. Actual restored hearing, after a single injection into her inner ear. Researchers used an AAV vector to deliver a working copy of the OTOF gene. Within four months, she could engage in daily conversation. Her hearing threshold improved from 106 decibels to 52. This wasn’t a mouse study. It worked in children and adults - ages 1 to 24. And it’s starting to feel like we see a new success story from CGT almost every day. Why this matters: → One of the first gene therapies to reverse sensory loss → Real human results, not just biomarkers → A future where single-dose cures aren’t sci-fi—they’re clinical reality Hearing loss affects over 430 million people worldwide. This trial just cracked open the door to something bigger.

For the first time in history, scientists have restored hearing in people born deaf by fixing a single faulty gene through viral gene therapy. This breakthrough is giving hope to millions living with hereditary hearing loss. The therapy works by delivering a corrected version of the defective gene directly into the cells of the inner ear. This gene is essential for producing proteins that allow sound waves to be translated into electrical signals for the brain. Once restored, patients who had never heard a sound began recognizing speech, music, and environmental noises. Early trials, especially in young children, showed dramatic improvements in speech recognition and auditory response. This is significant because the brain adapts most quickly during early development, making gene therapy particularly effective in younger patients. Beyond restoring hearing, this success demonstrates the vast potential of gene therapy to correct other congenital conditions. It represents a major step toward curing genetic diseases rather than managing them, and may one day make hereditary deafness a preventable condition.

For the first time in human history, scientists have restored hearing in people born completely deaf... all by repairing a single faulty gene. In one of the most groundbreaking medical advances ever, researchers have successfully restored hearing in patients born deaf using viral gene therapy... a treatment that targets the root cause, not just the symptoms. The therapy works by delivering a healthy copy of a defective gene directly into the inner ear cells responsible for detecting sound. This gene enables the body to produce the proteins that convert sound vibrations into electrical signals sent to the brain. In clinical trials, patients... many of them children who had never heard a sound before... began recognizing speech, music, and even subtle environmental noises like footsteps or rainfall. For parents, the moment their child reacted to sound for the first time was described as “life reborn.” This therapy focuses on a single gene mutation, but the implications are massive. Scientists believe this is just the beginning of using gene editing to cure hereditary disorders at their source... from blindness to muscular dystrophy, and even certain neurological conditions. Instead of managing symptoms for life, this could mean true genetic correction. Experts say early intervention is key, especially for children, since the brain’s ability to adapt to sound is strongest during early development. The success of this trial is now inspiring global efforts to expand gene therapy to millions affected by congenital hearing loss worldwide. This breakthrough doesn’t just restore hearing... it restores connection, communication, and the sound of life itself. 💛 references: reuters: Regeneron gene therapy improves hearing in 10 out of 11 children”, Reuters... media coverage of clinical trial results for gene therapy in congenital deafness. neurosciencenews: Gene Therapy Restores Hearing in Those with Deafness”, Neuroscience News... summary of trials restoring hearing in children and adults with congenital deafness via OTOF gene therapy Nature: Bilateral gene therapy in children with autosomal recessive deafness 9 (DFNB9)”, Nature Medicine... reports interim results of binaural OTOF gene therapy in pediatric patients. PMC: Otoferlin gene therapy restores hearing in deaf children”, PubMed Central (PMC)... detailed article describing AAV-mediated OTOF gene replacement to restore hearing in congenitally deaf children. Regeneron Investor Relations: Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial”, Regeneron (news release)... 10 of 11 children showed notable hearing improvements. PubMed: AAV-Mediated Gene Therapy Restores Hearing in Patients with …”, PubMed / NCBI... first clinical study demonstrating safety and efficacy of AAV–OTOF therapy in human patients. #fblifestyle #GeneTherapy

A groundbreaking experimental gene therapy has shown remarkable success in treating a specific form of congenital deafness caused by mutations in the OTOF gene, which encodes the protein otoferlin essential for transmitting sound signals from the inner ear's hair cells to the auditory nerve. In a recent single-arm clinical trial conducted across five hospitals in China, involving collaboration with researchers including those from Karolinska Institutet, ten patients aged between 1 and 24 years received a single injection of the therapy into the inner ear. The treatment utilizes a synthetic adeno-associated virus (AAV) vector to deliver a functional copy of the OTOF gene directly through the round window membrane at the base of the cochlea. This minimally invasive approach allows the virus to introduce the corrective genetic material into target cells without incorporating harmful viral genes, making it relatively safe based on established AAV platforms used in other gene therapies. Within one month, most participants began experiencing hearing improvements, with some noticing changes even sooner. By the six-month follow-up, all ten patients demonstrated significant gains: their average hearing threshold improved dramatically from around 106 decibels—comparable to loud mechanical noises like a car horn close by—to about 52 decibels, roughly the level of normal conversation. This restoration enabled better sound perception, speech recognition, and in some cases, enhanced quality of life previously limited by profound deafness or severe impairment. The therapy was well-tolerated with no serious adverse effects reported, marking a promising step toward biological restoration rather than reliance on devices like cochlear implants. While this targets a rare genetic subtype of deafness (autosomal recessive deafness 9, or DFNB9), success in every participant highlights the potential for gene therapies to address other hereditary hearing losses in the future. Larger trials and long-term data will be crucial to confirm durability and broader applicability, but these results signal an exciting era where precise genetic interventions could "cure" certain forms of deafness by fixing the root molecular cause at its source in the delicate inner ear environment.

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) has announced updated data for their investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin(OTOF) gene. This data was published in The New England Journal of Medicine and presented at the annual American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) meeting. These latest results from the pivotal CHORD trial show 11/12 participants have experienced clinically meaningful hearing improvements, including 3 who achieved normal hearing levels✅️ Until now, genetic OTOF-related hearing loss was considered permanent⚠️ This truly represents a new era in the treatment of #hearingloss🧏♂️ The CHORD #trial evaluated pediatric participants with profound hearing loss due to variants of the OTOF gene that received a single administration of DB-OTO via "intracochlear" infusion. The #trial met the primary endpoint with 9 participants experiencing hearing improvements at a threshold of ≤70 dBHL on behavioral pure tone audiometry (PTA) at week 24. This threshold corresponds to a clinical standard that typically does NOT require cochlear implantation and enables "natural" acoustic hearing🙂 The #US regulatory application for DB-OTO is planned for late 2025 pending discussions with the US FDA. DB-OTO received Orphan Drug, Rare Pediatric Disease, Fast Track & Regenerative Medicine Advanced Therapy designations from the #FDA. The European Medicines Agency also granted Orphan Drug Designation. Permanent congenital hearing loss is a significant unmet medical need that affects approximately 1.7 : 1000 children born in the US and ~50% of these cases have #genetic causes. OTOF hearing loss is ultra-rare, affecting 20-50 newborns per year in the US❗️ ~20,000 people in the US & EU have hearing loss caused by the mutations addressed by Regeneron’s therapy. Yet only those who DON'T already have #cochlearimplants in both ears would be eligible for DB-OTO❗️ This specific condition is caused by variants in the OTOF gene, which lead to a lack of a functional otoferlin protein that is critical for the communication between the inner ear sensory cells & the auditory nerve. DB-OTO is an investigational cell-selective, dual adeno-associated virus (AAV) vector #genetherapy designed to provide durable, physiological hearing to individuals with profound, congenital hearing loss caused by variants of OTOF gene. The #treatment aims to deliver a "working copy" of the OTOF gene to replace the "non-functional" otoferlin protein using a modified, non-pathogenic virus that is delivered via an infusion into the cochlea under general anesthesia. In this gene therapy, the newly introduced OTOF gene is under the control of a proprietary cell-specific Myo15 promoter, which is intended to restrict expression only to hair cells that normally express #otoferlin. Kudos👏 LEONARD S. SCHLEIFER, M.D. george yancopoulos Jonathon Whitton Teams Regeneron & Decibel Therapeutics **

BREAKING HEALTH NEWS “In a newly published early clinical trial, children born deaf due to a mutation in the OTOF gene were treated with gene therapy and showed significant hearing restoration — they previously could not hear, now they can detect sounds, perceive speech, and even localize sound. This demonstrates that repairing a defective gene in the inner ear can transform profound hereditary deafness in selected cases. However, this applies so far only to a specific gene/mutation type, the sample size is small, long‐term outcomes are still under observation, and it is not yet broadly applicable to all forms of deafness.” Mass Eye & Ear / Nature Medicine press release Harvard Medical School News NIDCD (National Institute on Deafness and Other Communication Disorders)

In a world-first medical breakthrough, researchers have successfully restored natural hearing by injecting stem cells directly into the inner ear, allowing damaged auditory nerves to regrow — something once considered irreversible. This pioneering therapy works by using lab-grown stem cells engineered to develop into auditory neurons — the vital nerve fibers that carry sound signals from the ear to the brain. Once injected, these cells integrate seamlessly with existing tissue, forming new neural connections. Within weeks, early clinical trial participants began showing significant improvements in sound clarity and speech recognition, confirming the regeneration of nerve pathways. The discovery marks a turning point in regenerative medicine and could transform treatment for the 430 million people worldwide living with hearing loss. Unlike hearing aids or cochlear implants that merely amplify sound, this therapy restores natural hearing function by repairing the biological system itself. Experts believe the same regenerative principles could be extended to other forms of neural damage, potentially opening doors for treatments of blindness, paralysis, and degenerative neurological disorders. While large-scale trials are ongoing, scientists say this represents the first real step toward curing hearing loss entirely — not just compensating for it. #StemCells #MedicalBreakthrough #HearingLoss #RegenerativeMedicine #ScienceNews